[go: up one dir, main page]

NO20030925D0 - Gem-substituted alpha V beta 3 integrin antagonists - Google Patents

Gem-substituted alpha V beta 3 integrin antagonists

Info

Publication number
NO20030925D0
NO20030925D0 NO20030925A NO20030925A NO20030925D0 NO 20030925 D0 NO20030925 D0 NO 20030925D0 NO 20030925 A NO20030925 A NO 20030925A NO 20030925 A NO20030925 A NO 20030925A NO 20030925 D0 NO20030925 D0 NO 20030925D0
Authority
NO
Norway
Prior art keywords
gem
beta
integrin antagonists
substituted alpha
alpha
Prior art date
Application number
NO20030925A
Other languages
Norwegian (no)
Other versions
NO20030925L (en
Inventor
Ish Kumar Khanna
Yi Yu
Hwang Fun-Lu
Nizal Samuel Chandrakumar
Renee M Huff
Mark Andrew Russell
Mark L Boys
Lori Ann Schretzman
Barbara B Chen
Bipinchandra Nanubhai Desai
Srinivasan Raj Nagarajan
Alan Frank Gasiecki
Thomas D Penning
Thomas Rogers
John Adam Wendt
Albert Khilevich
Yaping Wang
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20030925D0 publication Critical patent/NO20030925D0/en
Publication of NO20030925L publication Critical patent/NO20030925L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20030925A 2000-08-30 2003-02-27 Gem-substituted <alfa> v <beta> 3-integrin antagonists NO20030925L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918600P 2000-08-30 2000-08-30
PCT/US2001/026963 WO2002018340A1 (en) 2000-08-30 2001-08-29 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS

Publications (2)

Publication Number Publication Date
NO20030925D0 true NO20030925D0 (en) 2003-02-27
NO20030925L NO20030925L (en) 2003-04-24

Family

ID=22860154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030925A NO20030925L (en) 2000-08-30 2003-02-27 Gem-substituted <alfa> v <beta> 3-integrin antagonists

Country Status (16)

Country Link
EP (1) EP1313705A1 (en)
JP (1) JP2004510708A (en)
KR (1) KR20030027106A (en)
CN (1) CN1471512A (en)
AU (1) AU2001288515A1 (en)
BR (1) BR0113671A (en)
CA (1) CA2419699A1 (en)
CZ (1) CZ2003459A3 (en)
EA (1) EA200300226A1 (en)
IL (1) IL154496A0 (en)
MX (1) MXPA03001759A (en)
NO (1) NO20030925L (en)
NZ (1) NZ524159A (en)
PL (1) PL365729A1 (en)
WO (1) WO2002018340A1 (en)
ZA (1) ZA200301162B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060056377A (en) * 2003-08-13 2006-05-24 카이론 코포레이션 UBS-3 inhibitor and its use
WO2006043930A1 (en) * 2004-10-14 2006-04-27 Pharmacia Corporation Biphenyl integrin antagonists
CN101880270B (en) * 2009-05-07 2012-10-03 上海华升生物科技有限公司 Method for preparing 1,1-cyclopropanedimethyl cyclicsulfite
RS64535B1 (en) 2013-09-24 2023-09-29 Fujifilm Corp Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
RS66976B1 (en) * 2019-10-16 2025-07-31 Morphic Therapeutic Inc INHIBITION OF HUMAN INTEGRIN ALPHA4BETA7

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
CN1209063A (en) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 Vitronection receptor antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2002510328A (en) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
CN1273529A (en) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 Vitronection receptor antagonist

Also Published As

Publication number Publication date
CN1471512A (en) 2004-01-28
NO20030925L (en) 2003-04-24
KR20030027106A (en) 2003-04-03
IL154496A0 (en) 2003-09-17
JP2004510708A (en) 2004-04-08
ZA200301162B (en) 2004-05-12
EA200300226A1 (en) 2003-10-30
WO2002018340A1 (en) 2002-03-07
BR0113671A (en) 2004-01-06
EP1313705A1 (en) 2003-05-28
NZ524159A (en) 2004-08-27
MXPA03001759A (en) 2004-11-01
CA2419699A1 (en) 2002-03-07
PL365729A1 (en) 2005-01-10
CZ2003459A3 (en) 2003-09-17
AU2001288515A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
ATE232200T1 (en) NEUROPEPTIDE Y5 RECEPTOR ANTAGONISTS
NO20031268D0 (en) 4 Quinazolines
NO20032612D0 (en) CXCR3 antagonists
ATE437585T1 (en) ZIPPER
EE200000171A (en) New NPY antagonists
EP1229910A4 (en) INTEGRIN RECEPTOR ANTAGONISTS
DE60030831D1 (en) Zipper
NO20000542L (en) Endothelin antagonists
NO20004503D0 (en) Vitronectin receptor antagonists
NO20003694D0 (en) VLA-4 antagonists
NO20013013L (en) &lt;Alpha&gt; v &lt;beta&gt; 6-integrin
NO20031267L (en) 4 Quinazolines
DE60009219D1 (en) Linear zipper
NO20015237L (en) Integrin antagonists
NO20030925D0 (en) Gem-substituted alpha V beta 3 integrin antagonists
NO20016341D0 (en) Inhibitors for the integrin &lt;alfa&gt; v &lt;beta&gt; 6
EP1192168A4 (en) GALECTINE 11
NO20010620D0 (en) Vitronectin receptor antagonists
NO20020886D0 (en) Novel integrin &lt;alfa&gt; v &lt;beta&gt; 3 inhibitors
ITAT990002U1 (en) &#34;MILLENIUM DUE&#34; PROJECT
ITRC20000003A1 (en) &#34;BI ALA - IN&#34;
ITRC20000003V0 (en) &#34;BI ALA - IN&#34;
PT9613T (en) VYSOR 3 D
SE9901602D0 (en) Jet-thresh 2000
SE9900910D0 (en) FreezeBox 2000

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application